Galenica’s US partner Luitpold Pharmaceuticals has submitted a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for Injectafer, used to treat iron deficiency anaemia.

Injectafer is a non-dextran intravenous iron (i.v.) replacement therapy containing ferric carboxymaltose as its active pharmaceutical ingredient.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The submission includes the data from two randomised controlled clinical trials which assessed the cardiovascular risk profile of Injectafer.

One trial compares Injectafer to Venofer (iron sucrose injection) in patients with iron deficiency anaemia and chronic kidney disease, while the second study compares Injectafer to either oral or intravenous (i.v.) iron in patients with iron deficiency anaemia of various etiologies.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact